Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 7/20 | 0.49 |
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | CA9 | Q16790 | 7/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ELF3 | P78545 | 1/20 | 0.42 |
| ▸ | MED23 | Q9ULK4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216678 | 0.94 | HTR3A (0.52) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL15216688 | 0.90 | HTR3A (0.46) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL12185041 | 0.89 | CA1 (0.45) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL15218211 | 0.81 | CA1 (0.49) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL15146936 | 0.79 | FKBP1A (0.51) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL15216667 | 0.77 | CA1 (0.50) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL15218282 | 0.76 | CA1 (0.48) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL21282083 | 0.76 | CA1 (0.70) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL17245251 | 0.76 | CA1 (0.70) | HTR3ACA1CA2CA9CA12 | |
| SCHEMBL22855043 | 0.76 | CA1 (0.70) | HTR3ACA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170102387-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | ACADEMIA SINICA (TW) | 2017-04-13 | — | — | US | disclosed |
| US-9403855-B2 | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses | ACADEMIA SINICA (TW) | 2016-08-02 | — | — | US | disclosed |
| US-20130225532-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | ACADEMIA SINICA (TW) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225532-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | NEU1, NEU3, NEU4 | HTR3A 1355/4885CA1 1685/4885CA2 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.